<qa>  What is the name of the MCRC PATIENTs with WILD-TYPEPEAK: PANITUMUMAB PLUS MFOLFOX6 VS. BEVACIZUMAB PLUS MFOLFOX6 FOR FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER MCRC PATIENTS WITH WILD-TYPE KIRSTEN RAT SARCOMA-2 VIRUS KRAS TUMORS: 